Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure

Cardiovascular Research

Volumn 71, Issue 4, 2006, Pages 684-694

  Li, Yiwen ^a,d   Takemura, Genzou ^a   Okada, Hideshi ^a   Miyata, Shusaku ^a   Maruyama, Rumi ^a   Li, Longhu ^a   Higuchi, Masato ^b   Minatoguchi, Shinya ^a   Fujiwara, Takako ^c   Fujiwara, Hisayoshi ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c KYOTO WOMEN'S UNIVERSITY   (Japan)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cytokines; Heart failure; Myocardial infarction; Myocardial inflammation

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; STAT3 PROTEIN; STAT5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL INFILTRATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATORY CELL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TISSUE LEVEL;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CYTOKINES; ECHOCARDIOGRAPHY; ERYTHROPOIETIN, RECOMBINANT; FIBROBLASTS; HEART FAILURE, CONGESTIVE; HEMATOCRIT; HYDROGEN PEROXIDE; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MODELS, ANIMAL; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATION-REDUCTION; RANDOM ALLOCATION; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION; TIME; VENTRICULAR REMODELING;

EID: 33751568137     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2006.06.003     Document Type: Article

References (43)

1. Mancini D.M., Katz S.D., Lang C.C., LaManca J., Hudaihed A., and Androne A.S. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107 (2003) 294-299
2. Silverberg D.S., Wexler D., Sheps D., Blum M., Keren G., Baruch R., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37 (2001) 1775-1780
3. Chong Z.Z., Kang J.Q., and Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 106 (2002) 2973-2979
4. Wright G.L., Hanlon P., Amin K., Steenbergen C., Murphy E., and Arcasoy M.O. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18 (2004) 1031-1033
5. Bogoyevitch M.A. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 63 (2004) 208-216
6. Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112 (2003) 999-1007
7. Calvillo L., Latini R., Kajstura J., Leri A., Anversa P., Ghezzi P., et al. Recombinant human erythropoietin protects the myocardium from ischemic-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 100 (2003) 4802-4806
8. van der Meer P., Lipsic E., Henning R.H., Boddeus K., van der Velden J., Voors A.A., et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46 (2005) 125-133
9. Testa M., Yeh M., Lee P., Fanelli R., Loperfido F., Berman J.W., et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 28 (1996) 964-971
10. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., and Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27 (1996) 1201-1206
11. Ono K., Matsumori A., Shioi T., Furukawa Y., and Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 98 (1998) 149-156
12. Kinugawa S., Tsutsui H., Hayashidani S., Ide T., Suematsu N., Satoh S., et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 87 (2000) 392-398
13. Kumar D., Lou H., and Singal P.K. Oxidative stress and apoptosis in heart dysfunction. Herz 27 (2002) 662-668
14. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97 (2000) 10526-10531
15. Villa P., Bigini P., Mennini T., Agnello D., Laragione T., Cagnotto A., et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198 (2003) 971-975
16. Digicaylioglu M., and Lipton S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412 (2001) 641-647
17. Kawakami M., Sekiguchi M., Sato K., Kozaki S., and Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 276 (2001) 39469-39475
18. Rui T., Feng Q., Lei M., Peng T., Zhang J., Xu M., et al. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 65 (2005) 719-727
19. Li Y., Takemura G., Kosai K., Yuge K., Nagano S., Esaki M., et al. Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 107 (2003) 2499-2506
20. Toyokuni S., Tanaka T., Hattori Y., Nishiyama Y., Yoshida A., Uchida K., et al. Quantitative immunohistochemical determination of 8-hydroxy-2′-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest 76 (1997) 365-374
21. Wang L., Feng Z.P., Kondo C.S., Sheldon R.S., and Duff H.J. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ Res 79 (1996) 79-85
22. Legendre F., Dudhia J., Pujol J., and Bogdanowicz P. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin(IL)-6/soluble IL-6R down-regulation of type II collagen, Aggrecan core, and link protein transcription in articular chondrocytes. J Biol Chem 278 (2003) 2903-2912
23. Tsutsui H. Novel pathophysiological insight and treatment strategies for heart failure-lessons from mice and patients. Circ J 68 (2004) 1095-1103
24. Reimer K.A., Vander Heide R.S., and Richard V.J. Reperfusion in acute myocardial infarction: effect of timing and modulating factors in experimental models. Am J Cardiol 72 (1993) 13G-21G
25. Pfeffer M.A., and Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 81 (1990) 1161-1172
26. Hosenpud J.D., Bennett L.E., Keck B.M., Boucek M.M., and Novick R.J. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000. J Heart Lung Transplant 19 (2000) 909-913
27. Damås J.K., Gullestad L., Aass H., Simonsen S., Fjeld J., Wikeby L., et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effects of intravenous immunoglobulin. J Am Coll Cardiol 38 (2001) 187-193
28. Deveaux B., Scholz D., Hirche A., Kløverkorn W.P., and Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 18 (1997) 470-479
29. Damås J.K., Eiken H.G., Øie E., Bjerkeli V., Yndestad A., Ueland T., et al. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 47 (2000) 778-787
30. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., and Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 103 (2001) 2055-2059
31. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91 (2002) 988-998
32. Deswal A., Misra A., and Bozkurt B. The role of anti-cytokine therapy in the failing heart. Heart Fail Rev 6 (2001) 143-151
33. Suematsu N., Tsutsui H., Wen J., Kang D., Ikeuchi M., Ide T., et al. Oxidative stress mediated tumor necrosis factor α-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 107 (2003) 1418-1423
34. Meldrum D.R., Dinarello C.A., Shames B.D., Cleveland Jr. J.C., Cain B.S., Banerjee A., et al. Hydrogen peroxide induces tumor necrosis factor α-mediated cardiac injury by a p38 mitogen activated protein kinase-dependent mechanisms. Surgery 124 (1998) 291-296
35. Nakamura K., Fushimi K., Kouchi H., Mihara K., Miyazaki M., Ohe T., et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin II. Circulation 98 (1998) 794-799
36. Mehta J.L., Chen H.J., and Li D.Y. Protection of myocytes from hypoxia-reoxygenation injury by nitric oxide is mediated by modulation of transforming growth factor-β1. Circulation 105 (2002) 2206-2211
37. Ikeuchi M., Tsutsui H., Shiomi T., Matsusaka H., Matsushima S., Wen J., et al. Inhibition of TGF-β signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 64 (2004) 526-535
38. Border W.A., and Noble N.A. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331 (1994) 1286-1292
39. Moore K.W., de waal Malefyt R., Coffman R.L., and o'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19 (2001) 683-765
40. Jacoby J.J., Kalinowski A., Liu M.G., Zhang S.S., Gao Q., Chai G.X., et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci U S A 100 (2003) 12929-12934
41. Lopez N., Jiez J., and Fortuno M.A. Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. Cytokine 30 (2005) 282-292
42. Silverberg D.S., Wexler D., and Iaina A. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?. J Nephrol 17 (2004) 749-761
43. Li L., Takemura G., Li Y., Miyata S., Esaki M., Okada H., et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 113 (2006) 535-543